{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neovascular+%28Wet%29+AMD", "query": { "condition": "Neovascular (Wet) AMD" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 110, "total_pages": 11, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neovascular+%28Wet%29+AMD&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-24T10:07:23.631Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05407636", "title": "Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "AMD", "nAMD", "Wet Age-related Macular Degeneration", "wAMD", "WetAMD", "CNV" ], "interventions": [ { "name": "ABBV-RGX-314 Dose 1", "type": "GENETIC" }, { "name": "ABBV-RGX-314 Dose 2", "type": "GENETIC" }, { "name": "Aflibercept (EYLEA®)", "type": "BIOLOGICAL" } ], "intervention_types": [ "GENETIC", "BIOLOGICAL" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "89 Years", "sex": "ALL", "summary": "50 Years to 89 Years" }, "enrollment_count": 735, "start_date": "2022-01-13", "completion_date": "2027-11", "has_results": false, "last_update_posted_date": "2026-08-03", "last_synced_at": "2026-09-24T10:07:23.631Z", "location_count": 107, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Bakersfield, California + 94 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Beverly Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05407636" }, { "nct_id": "NCT02418754", "title": "Study of Intravitreal REGN2176-3 in Participants With Neovascular (\"Wet\") Age-Related Macular Degeneration (AMD)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neovascular Age-Related Macular Degeneration" ], "interventions": [ { "name": "REGN2176-3", "type": "DRUG" }, { "name": "Intravitreal Aflibercept Injection (IAI)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 505, "start_date": "2015-05-05", "completion_date": "2017-04-03", "has_results": true, "last_update_posted_date": "2020-10-26", "last_synced_at": "2026-09-24T10:07:23.631Z", "location_count": 75, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 72 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Arcadia", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Irvine", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02418754" }, { "nct_id": "NCT00509795", "title": "Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Macular Degeneration" ], "interventions": [ { "name": "ranibizumab", "type": "BIOLOGICAL" }, { "name": "aflibercept injection (VEGF Trap-Eye, BAY86-5321)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 1217, "start_date": "2007-08", "completion_date": "2011-07", "has_results": true, "last_update_posted_date": "2012-12-28", "last_synced_at": "2026-09-24T10:07:23.631Z", "location_count": 176, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 144 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00509795" }, { "nct_id": "NCT04964089", "title": "A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Wet Age-related Macular Degeneration" ], "interventions": [ { "name": "KSI-301", "type": "DRUG" }, { "name": "Aflibercept", "type": "DRUG" }, { "name": "Sham Procedure", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Kodiak Sciences Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 557, "start_date": "2021-06-23", "completion_date": "2023-04-06", "has_results": true, "last_update_posted_date": "2024-07-03", "last_synced_at": "2026-09-24T10:07:23.631Z", "location_count": 65, "location_summary": "Phoenix, Arizona • Springdale, Arkansas • Bakersfield, California + 60 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Bakersfield", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Fullerton", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04964089" }, { "nct_id": "NCT06556368", "title": "A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Wet Age-related Macular Degeneration" ], "interventions": [ { "name": "Tarcocimab tedromer", "type": "DRUG" }, { "name": "Tabirafusp tedromer", "type": "DRUG" }, { "name": "Aflibercept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kodiak Sciences Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 675, "start_date": "2024-08-23", "completion_date": "2027-08", "has_results": false, "last_update_posted_date": "2026-04-29", "last_synced_at": "2026-09-24T10:07:23.631Z", "location_count": 71, "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 66 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fullerton", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06556368" }, { "nct_id": "NCT00538538", "title": "Subretinal Lucentis for Hemorrhagic Age-related Macular Degeneration (AMD)", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Retinal Hemorrhage", "Macular Degeneration" ], "interventions": [ { "name": "vitrectomy with subretinal lucentis", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Corewell Health East", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 0, "start_date": "2007-09", "completion_date": "2008-10", "has_results": false, "last_update_posted_date": "2016-08-08", "last_synced_at": "2026-09-24T10:07:23.631Z", "location_count": 1, "location_summary": "Royal Oak, Michigan", "locations": [ { "city": "Royal Oak", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00538538" }, { "nct_id": "NCT07587515", "title": "Phase 1b/2a Study of EYC-0305 in Patients With Neovascular Age-related Macular Degeneration", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Neovascular (Wet) Age-Related Macular Degeneration" ], "interventions": [ { "name": "EYC-0305", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Eyconis INC.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 30, "start_date": "2026-05-19", "completion_date": "2028-05", "has_results": false, "last_update_posted_date": "2026-07-07", "last_synced_at": "2026-09-24T10:07:23.631Z", "location_count": 6, "location_summary": "Beverly Hills, California • Wake Forest, North Carolina • Erie, Pennsylvania + 3 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Wake Forest", "state": "North Carolina" }, { "city": "Erie", "state": "Pennsylvania" }, { "city": "Bellaire", "state": "Texas" }, { "city": "McAllen", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07587515" }, { "nct_id": "NCT05082415", "title": "Real-world Evaluation of Brolucizumab for the Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) (IRIS Study)", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Age-related Macular Degeneration (AMD)" ], "interventions": [ { "name": "Brolucizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 9456, "start_date": "2020-06-03", "completion_date": "2020-12-15", "has_results": false, "last_update_posted_date": "2021-10-27", "last_synced_at": "2026-09-24T10:07:23.631Z", "location_count": 1, "location_summary": "East Hanover, New Jersey", "locations": [ { "city": "East Hanover", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05082415" }, { "nct_id": "NCT04270747", "title": "A Study to Understand Effectiveness and Safety of ABP 938 Compared to Aflibercept (Eylea®) in Patients Suffering With Neovascular Age-related Macular Degeneration [Neovascular (Wet) AMD]", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Neovascular (Wet) Age-related Macular Degeneration (AMD)" ], "interventions": [ { "name": "ABP 938", "type": "DRUG" }, { "name": "Aflibercept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 576, "start_date": "2020-06-22", "completion_date": "2023-01-30", "has_results": true, "last_update_posted_date": "2025-09-10", "last_synced_at": "2026-09-24T10:07:23.631Z", "location_count": 41, "location_summary": "Phoenix, Arizona • Fullerton, California • La Jolla, California + 36 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Fullerton", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palm Desert", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04270747" }, { "nct_id": "NCT05131646", "title": "Extension Study to Evaluate the Long-term Outcomes of Subjects in the CLS-AX CLS1002-101 Study", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Neovascular Age-related Macular Degeneration" ], "interventions": [ { "name": "CLS-AX", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Clearside Biomedical, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 15, "start_date": "2021-10-08", "completion_date": "2023-01-05", "has_results": true, "last_update_posted_date": "2024-03-04", "last_synced_at": "2026-09-24T10:07:23.631Z", "location_count": 7, "location_summary": "Phoenix, Arizona • Mountain View, California • Sacramento, California + 4 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Mountain View", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Hagerstown", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05131646" } ] }